James Davis, PharmD, BCOP(@thisisJamesD) 's Twitter Profileg
James Davis, PharmD, BCOP

@thisisJamesD

Assistant professor & malignant hematology pharmacist @MUSCHollings #leukemia #lymphoma #myeloma opinions are my own

ID:1393178872808681479

calendar_today14-05-2021 12:18:35

213 Tweets

372 Followers

176 Following

Hamza Hashmi(@hhashmi87) 's Twitter Profile Photo

Hot off press: RWE of Safety & Efficacy of Teclistamab in 🙌👏🙏
➡️N=106, 42% EMD, 59% HR, 53% prior BCMA, 82% trial ineligible
➡️ORR 66%, CR 30%, mPFS 5.4m, 12m OS ~65%
➡️CRS (65%/1%), ICANS (14%/3%), infections 30%, IVIG 42%, Toci 42%
sciencedirect.com/science/articl…

Hot off press: RWE of Safety & Efficacy of Teclistamab in #RRMM🙌👏🙏 ➡️N=106, 42% EMD, 59% HR, 53% prior BCMA, 82% trial ineligible ➡️ORR 66%, CR 30%, mPFS 5.4m, 12m OS ~65% ➡️CRS (65%/1%), ICANS (14%/3%), infections 30%, IVIG 42%, Toci 42% sciencedirect.com/science/articl…
account_circle
Hamza Hashmi(@hhashmi87) 's Twitter Profile Photo

Poster # 4882: RWE of safety & efficacy of CAR T for with Extra-medullary disease
➡️N=132, 48% w EMD, median fu 7.2m
➡️No difference in CRS, ICANS, cytopenias, infections
➡️Similar ORR, CR, but ⬇️⬇️ PFS (6.5 vs 9.8m) and OS (12.9 vs 19.4m)
ASH

Poster # 4882: RWE of safety & efficacy of CAR T for #RRMM with Extra-medullary disease ➡️N=132, 48% w EMD, median fu 7.2m ➡️No difference in CRS, ICANS, cytopenias, infections ➡️Similar ORR, CR, but ⬇️⬇️ PFS (6.5 vs 9.8m) and OS (12.9 vs 19.4m) #ASH23 @ASH_hematology #MMSM
account_circle
Hamza Hashmi(@hhashmi87) 's Twitter Profile Photo

Poster#3503: Impact of Frailty on safety and efficacy of CAR T cell therapy for at
➡️N=136, 33% frail by SFI, frail pts with more HR disease (CG, EMD, TCR)
➡️No difference in CRS, infection, cytopenias, more g1-2 ICANS
➡️Inferior ORR, CR, PFS, OS in frail

Poster#3503: Impact of Frailty on safety and efficacy of CAR T cell therapy for #RRMM at #ASH23 ➡️N=136, 33% frail by SFI, frail pts with more HR disease (CG, EMD, TCR) ➡️No difference in CRS, infection, cytopenias, more g1-2 ICANS ➡️Inferior ORR, CR, PFS, OS in frail
account_circle
James Davis, PharmD, BCOP(@thisisJamesD) 's Twitter Profile Photo

SWOG Nivo-AVD vs BV-AVD in elderly patients. IMHO nivo-AVD is the new SOC for elderly HL patients with striking PFS and OS at just one year

SWOG Nivo-AVD vs BV-AVD in elderly patients. IMHO nivo-AVD is the new SOC for elderly HL patients with striking PFS and OS at just one year #ASH23
account_circle
Ajay Major, MD, MBA(@majorajay) 's Twitter Profile Photo

Nivo-AVD >> BV-AVD age 60+ S1826 Andrew M. Evens, DO, MBA, MSc :
- 97 pts, 47% IPS 4+
- 1-yr PFS 93% N-AVD (vs 64% BV-AVD); 👀those curves!
- less sepsis/infx in N-AVD; more neuropathy in BV (49% Gr 2+!)
- 14% NRM with BV-AVD! (v 4% N-AVD)
New SOC for older cHL!
ash.confex.com/ash/2023/webpr…

Nivo-AVD >> BV-AVD age 60+ S1826 @DrAEvens #ASH23: - 97 pts, 47% IPS 4+ - 1-yr PFS 93% N-AVD (vs 64% BV-AVD); 👀those curves! - less sepsis/infx in N-AVD; more neuropathy in BV (49% Gr 2+!) - 14% NRM with BV-AVD! (v 4% N-AVD) New SOC for older cHL! #lymsm ash.confex.com/ash/2023/webpr…
account_circle
Muzaffar Qazilbash(@Transplant_Doc) 's Twitter Profile Photo

Real-World Safety and Efficacy of Teclistamab for Rel/Ref Myeloma. N=102, >80% ineligible for MajesTEC-1, prior BCMA Rx: 55%. ORR: 64%, ORR with prior BCMA Rx: 57%, infections: 28%. 6-month PFS: 38% Danai Dima Hamza Hashmi Al-Ola A Abdallah MD (USMIRC) ash.confex.com/ash/2023/webpr…

account_circle
Al-Ola A Abdallah MD (USMIRC)(@Abdallah81MD) 's Twitter Profile Photo

Toxicity and Efficacy Outcomes of Teclistamab in RRMM Above the Age of 70 Years:
- ORR 70% and ≥CR: 30%
- PFS 5.4 months
- CRS G 1-2: 67%
- ICANS G 1-2:21%
- Thrombocytopenia G 3-4! 27%
- Infection rates 33%
- Hospital readmission rates 36%

Toxicity and Efficacy Outcomes of Teclistamab in RRMM Above the Age of 70 Years: - ORR 70% and ≥CR: 30% - PFS 5.4 months - CRS G 1-2: 67% - ICANS G 1-2:21% - Thrombocytopenia G 3-4! 27% - Infection rates 33% - Hospital readmission rates 36% #MedTwitter #ASH23 #USMIRC #MedEd…
account_circle
Al-Ola A Abdallah MD (USMIRC)(@Abdallah81MD) 's Twitter Profile Photo

Impact of Frailty on Outcomes after CAR T for Pts w RRMM: ORR, mPFS, OS was 83% vs 97% , 6.6 months vs 11 months, 14.4 months vs not reached (Frail vs non Frail, respectively). TRM was observed in 3 (4%) patients in the frail group

Impact of Frailty on Outcomes after CAR T for Pts w RRMM: ORR, mPFS, OS was 83% vs 97% , 6.6 months vs 11 months, 14.4 months vs not reached (Frail vs non Frail, respectively). TRM was observed in 3 (4%) patients in the frail group #USMIRC #MedTwitter #MedEd #mmsm #myeloma…
account_circle
Manni Mohyuddin(@ManniMD1) 's Twitter Profile Photo

5 real-world teclistamab experiences (with n>50) to date.

Mohan: tinyurl.com/yz4shbtp
Dima: tinyurl.com/tw799trf
Midha: tinyurl.com/jvbde9t4
Asoori: tinyurl.com/bdz494vw
Riedhammer: tinyurl.com/yc8eu457




Johannes Waldschmidt Leo Rasche

5 real-world teclistamab experiences (with n>50) to date. Mohan: tinyurl.com/yz4shbtp Dima: tinyurl.com/tw799trf Midha: tinyurl.com/jvbde9t4 Asoori: tinyurl.com/bdz494vw Riedhammer: tinyurl.com/yc8eu457 #mmsm #ASH23 @jo_waldschmidt @RascheLeo
account_circle
Al-Ola A Abdallah MD (USMIRC)(@Abdallah81MD) 's Twitter Profile Photo

Outstanding work by the team Danai Dima James Davis, PharmD, BCOP Hamza Hashmi Using Teclistimab in RW (55% were refractory to BDT): ORR was 64% for the entire cohort; ORR was 57%, 66% and 45% for patients who were BDT-refractory, penta-refractory, or had EMD, respectively Hira Shaikh

account_circle